Cislini Jeff 4
4 · Revolution Medicines, Inc. · Filed Jun 18, 2026
Research Summary
AI-generated summary of this filing
Revolution Medicines (RVMD) GC Jeff Cislini Sells 2,157 Shares
What Happened
Jeff Cislini, General Counsel of Revolution Medicines (RVMD), reported the sale of 2,157 shares on June 16, 2026. The shares were sold in open-market transactions at a weighted average price of $156.12 per share for total proceeds of approximately $336,749. The sale was executed in multiple trades with prices ranging from $156.1105 to $156.8251.
Key Details
- Transaction date: June 16, 2026; Form 4 filed June 18, 2026 (appears timely).
- Transaction type: Sale (S) — 2,157 shares; weighted average price $156.12; proceeds ~$336,749.
- Price range: $156.1105 to $156.8251; weighted average reported. Reporting person can provide trade-level details on request.
- Footnote F1: Sale made pursuant to a Rule 10b5-1 plan adopted May 31, 2023 to satisfy the reporting person's tax withholding obligations upon RSU vesting after July 15, 2023.
- Footnote F3/F4: Filing notes include 43,514 RSUs and 160 shares acquired under the ESPP on May 31, 2026. The filing excerpt provided does not state a single consolidated "shares owned after transaction" total.
Context
This sale was executed under a pre-established 10b5-1 plan to cover tax withholding tied to RSU vesting, which is a common, non-discretionary reason for insider sales and not necessarily an indicator of company outlook. The filing discloses the sale details and the nature of the plan; no additional inference about insider sentiment should be made from this routine, tax-related transaction.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3][F4]2026-06-16$156.12/sh−2,157$336,749→ 56,521 total
Footnotes (4)
- [F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8251. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]Includes 43,514 RSUs.
- [F4]Includes 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.